Category Archives: Financing

Bear hunting with biotech’s naysayers

Although it’s taken more than two years, biotech pessimists finally got to utter the phrase, “I told you so!” Yes, it finally arrived – a slip in the sector’s meteoric rise that saw, late in the first quarter, a drop…

Share

Bubbleology and Biotech’s Bull Run

Our recent analysis of biotech’s second quarter performance showed, for public biotech companies at least, their bull run that began more than 18 months ago is showing no signs of slowing down. Since the beginning of 2012 the Nasdaq Biotechnology…

Share

Force Care Foundation Brings Military Opportunities to Bio-Entrepreneurs

Last autumn, I was searching for a way to get rid of the nerve-zapping pain that hit every time the barometer made a steep jump. My face full of post-plane crash titanium and regenerated bone acted like a weather station….

Share

What Global Financial Crisis? Capital Markets Back Biotechs

It is that time of year again when we take the pulse of the industry at the close of the third quarter. Overall we find that it is performing well, more so for public biotechs than private ones. Despite the…

Share

Where’s Rube Goldberg When You Need Him?

What’s the difference between Congress and a Rube Goldberg contraption? They both use convoluted processes to accomplish a simple task, but the Goldberg invention still manages to keep the end result pretty simple. And while there may be some unintended…

Share

Biotech Fundraising Slows in 1H12, Tougher Times Ahead?

There is no doubt that 2011 was a hot financing year for biotech and it was always going to be a tough act to follow. Well the industry followed the script to the letter. According to a BioWorld Insight analysis,…

Share

A Stifled U.S. Biotech Sector: Is it Too Late to Recover?

BOSTON ‑ Amid all of the excitement that comes with the biopharma industry’s largest annual gathering in Boston this week, I’m worried about the future. The U.S. has lost too much ground ‑ due to the obvious partisan gridlock in…

Share

Biotech Fundraising Dips in Q112, But No Need to Panic

I’m seeing lots of references to BioWorld’s recent analysis by Cynthia Robbins-Roth showing that U.S.-based, VC-backed biotechs raised $391 million in the first quarter, a 34 percent increase compared to the same period last year. That’s good news, especially given…

Share

Defining Specialty Pharma: What is it, Can it Innovate, and Does it Matter?

The article I wrote last week for FierceBiotech on the relationship between Series A funding and innovation led to an interesting discussion with Bruce Booth, partner at Atlas Venture and biotech blogger extraordinaire. The crux of my article was this:…

Share

2010-12 Biotech IPOs Not Performing THAT Bad. Really.

What a difference two weeks makes. When I was researching last week’s BioWorld Insight cover – about how emerging biotech Verastem Inc., mature biotech Ironwood Pharmaceuticals Inc. and specialty pharma firm Clovis Oncology Inc. shared some surprising similarities in how…

Share